The present invention relates to a novel medical use of e.g.
4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the
cannabis CB.sub.1-receptor in combination with lipase inhibitors. Said
compounds are particularly suitable in combination with lipase inhibitors
in the manufacture of medicaments for the treatment and/or prophylaxis of
obesity in adolescent or in juvenile patients and/or for the treatment
and/or prophylaxis of drug induced obesity in juvenile as well as in
adolescent patients. The compounds have the general formula (I) 1
wherein the group Bb represents sulfonyl or carbonyl, and the substituents
R, R.sub.1, R.sub.2 and R.sub.3, and the group Aa are defined as shown in
the description. Preferred lipase inhibitors are orlistat, panclicins,
ATL-962 and/or lipstatin.
